Author of

• 25938

  +

  P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 26918

    +

    P2.01-113 - Prognostic Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients with Operable Stage III-N2  Non-Small Cell Lung Cancer (NSCLC) (ID 13455)

    16:45 - 18:00  |  Presenting Author(s): Luo-Sheng Yong
    • Abstract

    Background
    

    The therapeutic options for stage III-N2 positive NSCLC, including the diseases with ipsilateral mediastinal or subcarinal lymph node involvement, are with multidisciplinary approaches. The NCCN and ASCO guideline recommends the cisplatin-based adjuvant chemotherapy (Ad C/T). Meanwhile, some studies revealed the benefits of managing the N2 node disease with the neoadjuvant chemotherapy (Neo C/T) followed by surgery. We currently analyzed the clinical benefit of Neo C/T and Ad C/T for treating N2 positive NSCLC in a single-center cohort.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    The study was done retrospectively. A total of 258 patients with N2+ who received surgical resection in dept. of surgery, National Taiwan University Hospital during 2004 to 2016 were enrolled. The mean follow-up duration was 44 months. Both the overall survival (OS) and progression-free survival (PFS) were compared between C/T (-) (patients without chemotherapy treatment) , neo C/T, and Ad C/T groups using multivariate analysis and Kaplan-Meier estimates .

    4c3880bb027f159e801041b1021e88e8 Result
    

    There were 77, 55 and 126 patients in C/T (-), Neo C/T, and Ad C/T groups respectively. Patient's characteristics revealed the distributions of age and operation methods among these 3 groups were significantly differences. Patients treated with chemotherapy (combining Neo C/T and Ad C/T groups) were with significant reduced hazard for death compared to C/T (-) group (HR [95 % CI]= 0.55 [0.37-0.83), P=0.004). No significantly difference in overall survival was found between neo C/T and Ad C/T groups (HR [95 % CI]= 0.84 [0.54-1.32), P=0.451). The median overall survival time after surgery for the patients in neo C/T, and Ad C/T, and C/T (-) groups were also significant different (46.2, 56.9, and 26.9 months in C/T (-), Neo C/T, and Ad C/T groups respectively, P<0.001). However, there was no significant difference in patients received C/T or not in progression-free survival.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Both Ad C/T and Neo C/T provide clinical benefit for the patients with operable stage III N2 NSCLC . These is no significantly difference between Ad C/T and Neo C/T groups in both overall and progression-free survival .

    6f8b794f3246b0c1e1780bb4d4d5dc53